← Browse by Condition
Medical Condition
diabetic macular edema
Total Trials
7
Recruiting Now
7
Trial Phases
Phase 3, Phase 1, Phase 1, Phase 2
ClinicalMetric tracks all active clinical trials for diabetic macular edema sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.
- Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
- Phase 1–4 studies from early safety trials to post-marketing surveillance
- NIH, pharmaceutical sponsor, and academic medical center studies worldwide
- AI-powered plain-language summary available for every trial listing
Frequently Asked Questions — diabetic macular edema Clinical Trials
How many clinical trials are currently recruiting for diabetic macular edema?
ClinicalMetric currently tracks 7 actively recruiting clinical trials for diabetic macular edema, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 7. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for diabetic macular edema?
diabetic macular edema research spans Phase 1 (3 trials), Phase 2 (1 trial), Phase 3 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a diabetic macular edema clinical trial?
Eligibility criteria for diabetic macular edema trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 3
Phase 2 1
Phase 3 2
Top Sponsors
2 trials
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT07449936 Phase 3
Recruiting
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
Enrollment
240 pts
Location
United States
Sponsor
EyePoint Pharmaceuticals, Inc.
NCT07425522 Phase 1
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)
Enrollment
93 pts
Location
United States
Sponsor
Genentech, Inc.
NCT06549023
Recruiting
Single Session vs Multiple-Session Panretinal Photocoagulation for Treatment of Proliferative Diabetic Retinopathy
Enrollment
40 pts
Location
Sweden
Sponsor
Vastra Gotaland Region
NCT02669953
Recruiting
Aflibercept in Recurrent or Persistent CNV
Enrollment
80 pts
Location
Austria
Sponsor
Medical University of Vienna
NCT05916391 Phase 1
Recruiting
Gene Therapy for Diabetic Macular Edema
Enrollment
18 pts
Location
China
Sponsor
Frontera Therapeutics
NCT07449923 Phase 3
Recruiting
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
Enrollment
240 pts
Location
United States
Sponsor
EyePoint Pharmaceuticals, Inc.
NCT07458061 Phase 1, Phase 2
Recruiting
Kamuvudine-9 (K9) in Diabetic Macular Edema
Enrollment
10 pts
Location
United States
Sponsor
Dr. Bryan Strelow
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology